{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:04:54Z","timestamp":1782104694585,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Journal of Biological Sciences"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.sjbs.2020.11.044","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T22:39:20Z","timestamp":1606171160000},"page":"1128-1132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan"],"prefix":"10.1016","volume":"28","author":[{"given":"Nasar","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Nasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saqib","family":"Bajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Jawad Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afia","family":"Azher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehmina","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian Mukhtar Ul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam","family":"Rasul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firasat Ali","family":"Dogar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sjbs.2020.11.044_b0010","unstructured":"Latuda\u00ae (lurasidone HCl) tablets [package insert] Marlborough, MA: Sunovion Pharmaceuticals Inc, 2013. [Accessed March 25, 2015]. Available from: http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf."},{"key":"10.1016\/j.sjbs.2020.11.044_b0015","unstructured":"European Medicines Agency. Annex I: Summary of Product Characteristics. London, UK: European Medicines Agency, 2014. [Accessed March 25, 2015]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002713\/WC500164683.pdf."},{"issue":"2","key":"10.1016\/j.sjbs.2020.11.044_b0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-1241.2010.02587.x","article-title":"Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic","volume":"65","author":"Citrome","year":"2011","journal-title":"Int. J. Clin. Pract."},{"issue":"10","key":"10.1016\/j.sjbs.2020.11.044_b0025","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12325-012-0052-6","article-title":"Lurasidone in schizophrenia: new information about dosage and place in therapy","volume":"29","author":"Citrome","year":"2012","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.sjbs.2020.11.044_b0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3371\/CSRP.6.2.5","article-title":"Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?","volume":"6","author":"Citrome","year":"2012","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.sjbs.2020.11.044_b0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jad.2013.10.040","article-title":"Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"155","author":"Citrome","year":"2014","journal-title":"J. Affect Disord."},{"issue":"1","key":"10.1016\/j.sjbs.2020.11.044_b0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.sjbs.2020.11.044_b0045","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","article-title":"The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats","volume":"338","author":"Horiguchi","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.sjbs.2020.11.044_b0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.neuropharm.2013.01.023","article-title":"Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype","volume":"70","author":"Cates","year":"2013","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.sjbs.2020.11.044_b0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","article-title":"Is there a role for 5-HT1A agonists in the treatment of depression?","volume":"53","author":"Blier","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.sjbs.2020.11.044_b0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1755-5949.2010.00211.x","article-title":"Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson\u2019s disease","volume":"17","author":"Ohno","year":"2011","journal-title":"CNS Neurosci. Ther."},{"issue":"5","key":"10.1016\/j.sjbs.2020.11.044_b0065","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.2338","article-title":"Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies","volume":"28","author":"Preskorn","year":"2013","journal-title":"Hum. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.sjbs.2020.11.044_b0070","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1515\/dmdi-2014-0005","article-title":"Lurasidone drug-drug interaction studies: a comprehensive review","volume":"29","author":"Chiu","year":"2014","journal-title":"Drug Metabol. Drug Interact."},{"issue":"3","key":"10.1016\/j.sjbs.2020.11.044_b0075","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study","volume":"225","author":"Ogasa","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.sjbs.2020.11.044_b0080","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.sjbs.2020.11.044_b0085","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"9","key":"10.1016\/j.sjbs.2020.11.044_b0090","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.sjbs.2020.11.044_b0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80 mg\/day and 160 mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo-and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.sjbs.2020.11.044_b0100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.12m07992","article-title":"Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study","volume":"74","author":"McEvoy","year":"2013","journal-title":"J. Clin. Psychiatry."},{"issue":"3","key":"10.1016\/j.sjbs.2020.11.044_b0105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","article-title":"Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study","volume":"27","author":"Citrome","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.sjbs.2020.11.044_b0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study","volume":"147","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.sjbs.2020.11.044_b0115","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.euroneuro.2013.08.003","article-title":"Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo-and active-controlled study followed by a 6-month double-blind extension","volume":"23","author":"Harvey","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.sjbs.2020.11.044_b0120","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.schres.2011.01.004","article-title":"Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs ziprasidone","volume":"127","author":"Harvey","year":"2011","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.sjbs.2020.11.044_b0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.sjbs.2020.11.044_b0130","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1176\/appi.ajp.163.3.426","article-title":"The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity","volume":"163","author":"Keefe","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.sjbs.2020.11.044_b0135","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1017\/S109285291300093X","article-title":"Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study","volume":"19","author":"Citrome","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.sjbs.2020.11.044_b0145","doi-asserted-by":"crossref","unstructured":"Tandon, R., Loebel, A., Phillips, D., et al., 2014. EPA-1722 \u2013 A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia [abstract]. Eur. Psychiatry 29(Supplement 1), S372.","DOI":"10.1016\/S0924-9338(14)78861-3"},{"key":"10.1016\/j.sjbs.2020.11.044_b0150","article-title":"Dose escalation in early nonresponders to 80 mg\/day of lurasidone: The Optimize study; Presented at the annual meeting of the American College of Neuropsychopharmacology","author":"Loebel","year":"2014","journal-title":"Phoenix."},{"key":"10.1016\/j.sjbs.2020.11.044_b0155","unstructured":"Sunovion ProFile\u2122 [webpage on the Internet]Marlborough, MA: Sunovion Pharmaceuticals Inc; 2015. [Accessed March 25, 2015]. (Metabolic parameters: metabolic parameters evaluated in multiple bipolar depression studies for 6 weeks and 12 weeks). Available from: https:\/\/www.sunovionprofile.com\/sp\/latuda-bp\/metabolic-parameters.html."},{"issue":"2","key":"10.1016\/j.sjbs.2020.11.044_b0160","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852913000904","article-title":"Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia","volume":"19","author":"Loebel","year":"2014","journal-title":"CNS Spectr."},{"issue":"9896","key":"10.1016\/j.sjbs.2020.11.044_b0165","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.sjbs.2020.11.044_b0170","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4088\/JCP.12m08084","article-title":"Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study","volume":"74","author":"Stahl","year":"2013","journal-title":"J. Clin. Psychiatry"}],"container-title":["Saudi Journal of Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319562X20306082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319562X20306082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:02:34Z","timestamp":1761152554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319562X20306082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1319562X20306082"],"URL":"https:\/\/doi.org\/10.1016\/j.sjbs.2020.11.044","relation":{},"ISSN":["1319-562X"],"issn-type":[{"value":"1319-562X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan","name":"articletitle","label":"Article Title"},{"value":"Saudi Journal of Biological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sjbs.2020.11.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}